This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Sami Labs Limited. Active years: 2015.
Company Filing History:
Years Active: 2015
Title: Innovations by Jeffrey Reinhardt
Introduction
Jeffrey Reinhardt is an accomplished inventor based in Carson City, NV (US). He has made significant contributions to the field of bioavailable stilbenoids, with a focus on their therapeutic applications. With a total of 2 patents, Reinhardt's work is paving the way for advancements in health and wellness.
Latest Patents
Reinhardt's latest patents include innovative compositions that utilize orally bioavailable stilbenoids. One notable patent is for a novel, bioavailable stilbenoid, 3,5-dimethoxy-3,4'-dihydroxystilbene, which has shown an unexpected enhanced ability to prevent lipid accumulation during the differentiation of adipocytes. This discovery is significant for inhibiting adipogenesis and offers potential applications in anti-obesity and anti-cellulite therapies. Additionally, the patent discloses the enhanced activation of SIRT-1, a key protein involved in cellular regulation, by the stilbenoid compounds. Another patent focuses on sirtuin modulating compositions that include both 3,5-dimethoxy-3,4'-dihydroxystilbene and 2,3',5',6-tetrahydroxy-trans-stilbene, highlighting their potential in various therapeutic applications.
Career Highlights
Reinhardt is currently associated with Sami Labs Limited, where he continues to innovate and develop new formulations. His work is characterized by a commitment to enhancing the efficacy of natural compounds for health benefits.
Collaborations
Throughout his career, Reinhardt has collaborated with notable professionals in the field, including Krishnamani Jayaraman and Muhammed Majeed. These collaborations have contributed to the advancement of research and development in bioavailable compounds.
Conclusion
Jeffrey Reinhardt's contributions to the field of bioavailable stilbenoids are noteworthy and have the potential to impact health and wellness significantly. His innovative patents and collaborations reflect a dedication to advancing therapeutic applications.
